Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $506000.0.

  • Puma Biotechnology's Cash from Investing Activities rose 9536.68% to $506000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 5613.59%. This contributed to the annual value of -$20.4 million for FY2024, which is 686.54% down from last year.
  • Puma Biotechnology's Cash from Investing Activities amounted to $506000.0 in Q3 2025, which was up 9536.68% from -$11.2 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Cash from Investing Activities ranged from a high of $11.2 million in Q3 2023 and a low of -$19.1 million during Q1 2024
  • Its 5-year average for Cash from Investing Activities is -$2.8 million, with a median of -$2.3 million in 2024.
  • In the last 5 years, Puma Biotechnology's Cash from Investing Activities soared by 27892.62% in 2022 and then plummeted by 170000.0% in 2025.
  • Puma Biotechnology's Cash from Investing Activities (Quarter) stood at $4.6 million in 2021, then tumbled by 356.94% to -$11.9 million in 2022, then surged by 31.19% to -$8.2 million in 2023, then surged by 71.6% to -$2.3 million in 2024, then soared by 121.81% to $506000.0 in 2025.
  • Its Cash from Investing Activities stands at $506000.0 for Q3 2025, versus -$11.2 million for Q2 2025 and $1.5 million for Q1 2025.